Amarin Corp Plc (AMRN)

[Biobillionair]

Later this week: Amarin to Present at the Jefferies 2013 Global Healthcare Conference

1) I expect we get combo dosing data, perhapse with more Anchor data PR Thursday AM.

2) Depending on how aggressive Amarin feels like being, we may get an AZN quote: Pascal Soriot, Chief Executive Officer of AstraZeneca said: “The number of people with elevated triglyceride levels is rising rapidly across the world, due in part to the increasing prevalence of obesity and diabetes. There is a clear need for effective and convenient alternatives to some of the existing treatments. Epanova offers real potential both as a distinctive monotherapy for the treatment of hypertriglyceridemia and in combination with Crestor for patients at high risk of adverse cardiovascular events. This is an exciting acquisition that clearly complements our existing portfolio in cardiovascular and metabolic disease, one of our core therapy areas.”
http://www.astrazeneca.com/Media/Press-releases/Article/20130528-omthera
Also note, AF's silence since the AZN intial comment;). He doesn't bash the big boys, typical bully mentality.

3) And then perhapse a gental reminder of Amarin's IP statin protection. Those that know a small amount about patent law should know that an Epanova/Statin combo would violate Amarin's exciting patents and a new granted patent would be too obvious to be granted.

4) We should also hear a time frame for an Anchor launch, AZN improved our Royality Partnership possibilities with Pascal's statement.

5) Elan has always been an Amarin financial partner, these are well documented in Amarin's early days. An Amarin contract could be pushed up with Royalty Pharma and Elan hostIlities escalating.

----Good Luck All! Even to those who thought shorting at this point was a good idea, I expect you will need the most luck. At some time this summer Amarin is due for a 20-50 million shares traded day and a new price range.

Williams